Dr. James Arnold
Reader and Head of Tumor Immunology Group
King's College London
James started his career at the University of Oxford for his PhD where he studied the complement system under the supervision of Dr. Bob Sim. After his PhD, James went on to study with Prof. Douglas Fearon at the University of Cambridge in the CRUK Cambridge Research Institute. It was under Prof. Fearon’s mentorship that James became interested in tumor immunology and discovered that a population of cancer-associated fibroblasts was pivotal to suppressing anti-tumor immunity using murine models of cancer. In 2010, James became a Fellow of the Cancer Research Institute (NY), Irvington Institute Research Program, and in 2012 moved to King’s College London to establish the Tumor Immunology Group as a Lecturer. James was promoted to the position of Reader in Tumor Immunology in 2021. James’ academic group focuses on translational approaches to harness the anti-tumor immune response against cancer. James’ team have an interest in tumor-associated macrophages (TAMs) and their role in immune suppression and have taken a recent interest in subsets of perivascular TAMs and their niches that influence T cell anti-tumor immunity in cancer (the topic of James’ talk). James’ team also has an interest in CAR T cell technologies and his team developed a hypoxia-sensing CAR T platform that led to a commercial spinout, Korecyte Bio, a cellular immunotherapy biotech focused on developing hypoxia-sensing CAR approaches towards clinical translation.